Wescott Financial Advisory Group’s Gilead Sciences GILD Stock Holding History

Wescott Financial Advisory Group’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$469K	Sell	3,710 -4	-0.1%	-$527	0.04%	138
2026 Q1	$518K	Buy	3,714 +46	+1%	+$6.44K	0.05%	125
2025 Q4	$450K	Buy	3,668 +122	+3%	+$14.8K	0.04%	132
2025 Q3	$394K	Sell	3,546 -5	-0.1%	-$568	0.04%	136
2025 Q2	$394K	Sell	3,551 -19	-0.5%	-$2.02K	0.04%	131
2025 Q1	$400K	Buy	3,570 +17	+0.5%	+$1.75K	0.04%	123
2024 Q4	$328K	Buy	3,553 +182	+5%	+$16.4K	0.03%	134
2024 Q3	$283K	Buy	3,371 +6	+0.2%	+$458	0.03%	151
2024 Q2	$231K	Buy	+3,365	New	+$225K	0.03%	155

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wescott Financial Advisory Group's GILD Position: Q2 2026 in Review

Wescott Financial Advisory Group reduced its Gilead Sciences (GILD) stake by 0.11% in Q2 2026, selling an estimated $527 and leaving 3,710 shares worth $469K. The position accounts for 0.04% of the portfolio, ranked #138.

Wescott Financial Advisory Group first reported a position in GILD in Q2 2024 and has held it in 9 quarters since. The position peaked at $518K in Q1 2026. 2,284 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Wescott Financial Advisory Group held 3,710 shares of Gilead Sciences worth $469K as of Q2 2026.
Wescott Financial Advisory Group sold 4 Gilead Sciences shares in Q2 2026, an estimated $527.
Gilead Sciences made up 0.04% of Wescott Financial Advisory Group's portfolio in Q2 2026, its #138 holding.
Wescott Financial Advisory Group first reported a position in Gilead Sciences in Q2 2024 and has held it in 9 quarters since.
Wescott Financial Advisory Group's Gilead Sciences position peaked at $518K in Q1 2026.
2,284 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Wescott Financial Advisory Group's 13F filing for Q2 2026, filed 4 Aug 2026.